Search results
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 6 days agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 6 days agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Mesothelioma
Health· 5 days agoRelated conditions include: Chronic obstructive pulmonary disease (COPD): Affects your breathing ability and blocks airflow Coronary artery disease...
Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript Highlights: St
Guru Focus· 7 days agoTotal Revenue: $7.4 billion, up 22% year-over-year.Product Sales: Excluding Horizon products, increased 6% year-over-year.Operating Margin: Q1 operating margin
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 6 days agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi's sBLA for Dupixent for COPD treatment was accepted by the FDA for priority review, highlighting ...
Could dietary changes help treat pulmonary hypertension?
Medical News Today· 7 hours agoAbout 1% of the world’s population lives with pulmonary hypertension, which currently has no cure....
Smoking on oxygen killed 3 York countians this year. A $4.45 device might have saved them
Hanover Evening Sun via Yahoo News· 2 days ago"Typically, but not all the time, people who are on supplemental oxygen have a respiratory problem,...
Earnings call: Amgen reports robust Q1 2024 sales and pipeline progress
Investing.com· 6 days agoThe biotechnology company has seen a 22% increase in sales, driven by key products such as Repatha,...
Regeneron misses earnings, revenue expectations
Investing.com· 7 days agoRegeneron (NASDAQ: REGN ) experienced a slight decline in its stock price, falling 1.82% after reporting first-quarter earnings and revenue that fell...